146 related articles for article (PubMed ID: 24875051)
1. The gender of cell lines matters when screening for novel anti-cancer drugs.
Nunes LM; Robles-Escajeda E; Santiago-Vazquez Y; Ortega NM; Lema C; Muro A; Almodovar G; Das U; Das S; Dimmock JR; Aguilera RJ; Varela-Ramirez A
AAPS J; 2014 Jul; 16(4):872-4. PubMed ID: 24875051
[TBL] [Abstract][Full Text] [Related]
2. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Kong D; Yamori T
Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246
[TBL] [Abstract][Full Text] [Related]
3. Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery.
Evensen NA; Li J; Yang J; Yu X; Sampson NS; Zucker S; Cao J
PLoS One; 2013; 8(12):e82811. PubMed ID: 24349367
[TBL] [Abstract][Full Text] [Related]
4. Development of a cell-based pathway modulator screening system to screen the targeted cancer therapeutic candidates.
Panneerpandian P; Ganesan K
Hum Cell; 2021 Mar; 34(2):445-456. PubMed ID: 33405176
[TBL] [Abstract][Full Text] [Related]
5. Large-Scale Drug Screens Support Precision Medicine.
Gray JW; Mills GB
Cancer Discov; 2015 Nov; 5(11):1130-2. PubMed ID: 26526695
[TBL] [Abstract][Full Text] [Related]
6. 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems.
Howes AL; Richardson RD; Finlay D; Vuori K
PLoS One; 2014; 9(9):e108283. PubMed ID: 25247711
[TBL] [Abstract][Full Text] [Related]
7. Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.
Feng R; Rios JA; Onishi T; Lokshin A; Gorelik E; Lentzsch S
Leuk Res; 2010 Jul; 34(7):917-24. PubMed ID: 20116850
[TBL] [Abstract][Full Text] [Related]
8. Precision multidimensional assay for high-throughput microRNA drug discovery.
Haefliger B; Prochazka L; Angelici B; Benenson Y
Nat Commun; 2016 Feb; 7():10709. PubMed ID: 26880188
[TBL] [Abstract][Full Text] [Related]
9. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide.
Fan-Minogue H; Bodapati S; Solow-Cordero D; Fan A; Paulmurugan R; Massoud TF; Felsher DW; Gambhir SS
Mol Cancer Ther; 2013 Sep; 12(9):1896-905. PubMed ID: 23825064
[TBL] [Abstract][Full Text] [Related]
10. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures.
Boehnke K; Iversen PW; Schumacher D; Lallena MJ; Haro R; Amat J; Haybaeck J; Liebs S; Lange M; Schäfer R; Regenbrecht CR; Reinhard C; Velasco JA
J Biomol Screen; 2016 Oct; 21(9):931-41. PubMed ID: 27233291
[TBL] [Abstract][Full Text] [Related]
11. A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening.
Gupta A; Gautam P; Wennerberg K; Aittokallio T
Commun Biol; 2020 Jan; 3(1):42. PubMed ID: 31974521
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
[TBL] [Abstract][Full Text] [Related]
13. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
14. High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.
Hongisto V; Jernström S; Fey V; Mpindi JP; Kleivi Sahlberg K; Kallioniemi O; Perälä M
PLoS One; 2013; 8(10):e77232. PubMed ID: 24194875
[TBL] [Abstract][Full Text] [Related]
15. Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.
Krausz E; de Hoogt R; Gustin E; Cornelissen F; Grand-Perret T; Janssen L; Vloemans N; Wuyts D; Frans S; Axel A; Peeters PJ; Hall B; Cik M
J Biomol Screen; 2013 Jan; 18(1):54-66. PubMed ID: 22923784
[TBL] [Abstract][Full Text] [Related]
16. Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
Rao TD; Rosales N; Spriggs DR
Mol Cancer Ther; 2011 Oct; 10(10):1939-48. PubMed ID: 21817115
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiologically relevant in vitro tumor models for drug screening.
Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
[TBL] [Abstract][Full Text] [Related]
18. An image-based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cells.
Zhu W; Lee CY; Johnson RL; Wichterman J; Huang R; DePamphilis ML
Mol Cancer Res; 2011 Mar; 9(3):294-310. PubMed ID: 21257818
[TBL] [Abstract][Full Text] [Related]
19. In vitro assays for anticancer drug discovery--a novel approach based on engineered mammalian cell lines.
Gonzalez-Nicolini V; Fussenegger M
Anticancer Drugs; 2005 Mar; 16(3):223-8. PubMed ID: 15711174
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput image-based screen for the identification of Bax/Bak-independent caspase activators against drug-resistant cancer cells.
Seervi M; Sobhan PK; Mathew KA; Joseph J; Pillai PR; Santhoshkumar TR
Apoptosis; 2014 Jan; 19(1):269-84. PubMed ID: 24220853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
